[go: up one dir, main page]

CN115812081A - 抗ctla-4抗体及其用途 - Google Patents

抗ctla-4抗体及其用途 Download PDF

Info

Publication number
CN115812081A
CN115812081A CN202180049546.4A CN202180049546A CN115812081A CN 115812081 A CN115812081 A CN 115812081A CN 202180049546 A CN202180049546 A CN 202180049546A CN 115812081 A CN115812081 A CN 115812081A
Authority
CN
China
Prior art keywords
seq
amino acid
variable region
chain variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049546.4A
Other languages
English (en)
Inventor
潘志卫
姚剑
张静
周岳华
刘洪川
武海
姚盛
冯辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Junshi Biosciences Co Ltd
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd, Suzhou Junmeng Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of CN115812081A publication Critical patent/CN115812081A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种与CTLA‑4特异性结合的抗体或其抗原结合片段和包含其的组合物。还提供了编码抗体或其抗原结合片段的核酸分子，用于表达抗体或其抗原结合片段的载体和宿主细胞，以及抗体或其抗原结合片段的治疗和诊断方法和用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202180049546.4A 2020-07-21 2021-07-21 抗ctla-4抗体及其用途 Pending CN115812081A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020107081058 2020-07-21
CN202010708105 2020-07-21
PCT/CN2021/107707 WO2022017428A1 (zh) 2020-07-21 2021-07-21 抗ctla-4抗体及其用途

Publications (1)

Publication Number Publication Date
CN115812081A true CN115812081A (zh) 2023-03-17

Family

ID=79728492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049546.4A Pending CN115812081A (zh) 2020-07-21 2021-07-21 抗ctla-4抗体及其用途

Country Status (7)

Country Link
US (1) US20230295301A1 (zh)
EP (1) EP4201958A4 (zh)
CN (1) CN115812081A (zh)
AU (1) AU2021311701A1 (zh)
BR (1) BR112023000826A2 (zh)
CA (1) CA3186108A1 (zh)
WO (1) WO2022017428A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116640216A (zh) * 2023-07-20 2023-08-25 合源生物科技(天津)有限公司 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116440263A (zh) * 2022-01-17 2023-07-18 上海君实生物医药科技股份有限公司 抗ctla-4抗体药物组合物及其用途
WO2023240287A1 (en) * 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024056049A1 (zh) * 2022-09-16 2024-03-21 同润生物医药(上海)有限公司 具有pH依赖性的抗CTLA4抗体或抗原结合片段

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
TR201909609T4 (tr) 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
CN101074264B (zh) * 2006-05-17 2011-08-17 上海抗体药物国家工程研究中心有限公司 一种重组抗ctla4单克隆抗体及其制备方法和用途
CN102134276A (zh) * 2010-01-22 2011-07-27 上海抗体药物国家工程研究中心有限公司 一种抗ctla-4嵌合抗体
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
WO2017087870A1 (en) * 2015-11-18 2017-05-26 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
DK3551660T5 (da) * 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CN110272490B (zh) * 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 靶向ctla-4抗体、其制备方法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116640216A (zh) * 2023-07-20 2023-08-25 合源生物科技(天津)有限公司 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用
CN116640216B (zh) * 2023-07-20 2023-11-10 合源生物科技(天津)有限公司 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用

Also Published As

Publication number Publication date
US20230295301A1 (en) 2023-09-21
AU2021311701A1 (en) 2023-02-16
CA3186108A1 (en) 2022-01-27
WO2022017428A1 (zh) 2022-01-27
EP4201958A1 (en) 2023-06-28
BR112023000826A2 (pt) 2023-02-07
EP4201958A4 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
KR102068600B1 (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
CN115812081A (zh) 抗ctla-4抗体及其用途
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
JPWO2019175216A5 (zh)
JPWO2019175220A5 (zh)
CN108138172B (zh) 抗体
CN115991778A (zh) 抗pd-l1抗体及其用途
JP2024530451A (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
EP4347655A1 (en) Anti-ccr8 antibodies and uses thereof
CA3180188A1 (en) Anti-flt3 antibodies and compositions
TW202229343A (zh) Fgfr3抗體及使用方法
CN109721656B (zh) 靶向rankl的治疗性抗体
EP4490192A1 (en) Cd28 bispecific antibodies for targeted t cell activation
TW202221041A (zh) 一種結合人pd-l1的抗體
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
AU2020390028B2 (en) Pharmaceutical composition, preparation method therefor and use thereof
RU2020128108A (ru) Антитело против cd25 для опухоль-специфической клеточной деплеции
JP2023109923A (ja) グロボｈに対するヒト化抗体および癌治療におけるその使用
WO2022166987A1 (zh) 结合lag-3的抗体及其用途
WO2023193732A1 (zh) 一种抗ccr8抗体或其抗原结合片段
KR20240099351A (ko) Gprc5d에 결합하는 항체 및 그 용도
WO2023025194A1 (zh) Fap/cd40结合分子及其医药用途
CN112805297B (zh) 抗人类pd-l1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089437

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20241227

Address after: 13 / F, building 2, No.36 and 58 Haiqu Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201210

Applicant after: SHANGHAI JUNSHI BIOSCIENCES Co.,Ltd.

Country or region after: China

Address before: 13th Floor, Building 2, No. 36 and 58 Haiqu Road, Pudong New Area Free Trade Zone, Shanghai, China, October 2012

Applicant before: SHANGHAI JUNSHI BIOSCIENCES Co.,Ltd.

Country or region before: China

Applicant before: SUZHOU JUNMENG BIOSCIENCES Co.,Ltd.

TA01 Transfer of patent application right